---
title: "Citi Raises HUTCHMED  TP to HKD45.3, Maintains Buy/High Risk Rating and Top Pick Status"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306225953.md"
description: "Citi raised HUTCHMED's target price to HKD45.3 from HKD43.2, maintaining a Buy rating and Top Pick status. This follows the earlier-than-expected NMPA approval of sovleplenib, the company's first self-developed hematology product. The broker increased revenue forecasts for 2026-2028 by 1% and net profit forecasts by 2-4%, incorporating sales from 2026 with a 100% probability of success. The approval reduces strategic risks and accelerates commercialization in the autoimmune hematologic disease market."
datetime: "2026-11-20T06:14:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306225953.md)
  - [en](https://longbridge.com/en/news/306225953.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306225953.md)
generator: "portal-rs"
---

# Citi Raises HUTCHMED  TP to HKD45.3, Maintains Buy/High Risk Rating and Top Pick Status

Citi published a research report stating that HUTCHMED (00013.HK) -0.440 (-2.048%) Short selling $6.57M; Ratio 21.740% announced that sovleplenib has received approval from China's National Medical Products Administration (NMPA), ahead of the company's guidance for approval in 1H27. Sovleplenib is a highly selective oral Syk inhibitor and represents the company's first self-developed hematology product to enter commercialization, marking another successful expansion beyond its established oncology business.

The broker noted that the approval reduces strategic risks for HUTCHMED in immunology/hematology and enables the company to enter the autoimmune hematologic disease market, broadening its commercial portfolio beyond oncology. The asset has already achieved positive pivotal data in immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), supporting further lifecycle expansion. Citi had previously assumed approval in 1H27, and the earlier-than-expected approval will help accelerate commercialization, with initial sales contribution potentially arriving earlier than previously forecast. The approval also eases investor concerns regarding CMC preparedness, while global regulatory and manufacturing risks have declined significantly.

Citi raised its revenue forecasts for HUTCHMED for each of 2026 to 2028 by 1%, while net profit forecasts were increased by 4%, 2% and 4%, respectively, as the broker now incorporates sovleplenib sales from 2026 and raises the probability of success (POS) to 100%. Citi lifted the TP from HKD43.2 to HKD45.3, maintained its Buy/High Risk rating, and retained the stock as its top pick. (da/j)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-20 12:25.)

### Related Stocks

- [HCM.US](https://longbridge.com/en/quote/HCM.US.md)
- [HAWG.US](https://longbridge.com/en/quote/HAWG.US.md)
- [00013.HK](https://longbridge.com/en/quote/00013.HK.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)

## Related News & Research

- [UBS: HUTCHMED  Sovleplenib Approved in China for ITP and wAIHA Treatment, Positive and Better Than Expected](https://longbridge.com/en/news/306233318.md)
- [HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS® | HCM Stock News](https://longbridge.com/en/news/305611428.md)
- [Citi: 2026 NRDL Negotiation Results Released; Drugmakers Say Price Cuts Mild and Manageable](https://longbridge.com/en/news/306083646.md)
- [HUTCHMED (China) Limited EMA, Japan Accept Reviews for Savolitinib + Osimertinib](https://longbridge.com/en/news/303871950.md)
- [UBS: Positive SAFFRON and SANOVO Data for HUTCHMED  Show Potential of Savolitinib](https://longbridge.com/en/news/303166946.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**